Literature DB >> 10858970

The vascular endothelium in chronic renal failure.

S T Morris1, A G Jardine.   

Abstract

Chronic renal failure (CRF) is associated with a 20-fold increased risk of cardiovascular death, two principal mechanisms being: sudden, arrhythmic death associated with left ventricular hypertrophy, and ischaemic heart disease, associated with accelerated atherosclerosis. In recent years, the vascular endothelium has been recognised as a large and complex endocrine organ, with many important physiological functions including the control of vascular tone. Endothelial dysfunction, commonly characterised by reduced production of the vasodilator nitric oxide (NO), is thought to be a key initial event in the development of atherosclerosis and is present in patients with hypertension and hyperlipidaemia. While these cardiovascular risk factors are also prevalent in CRF, other factors more specific to uraemia such as accumulation of homocysteine and asymmetric dimethylarginine (endogenous inhibitor of NO synthase) may impair endothelial function. Modulation of endothelial function in CRF may offer a novel strategy to reduce cardiovascular disease.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10858970

Source DB:  PubMed          Journal:  J Nephrol        ISSN: 1121-8428            Impact factor:   3.902


  10 in total

1.  On-Pump versus Off-pump Myocardial Revascularization in Patients with Renal Insufficiency: Early and Mid-term Results.

Authors:  Hwan Wook Kim; Jae-Won Lee; Hyung Gon Je; Soo Hwan Choi; Keon Hyon Jo; Hyun Song
Journal:  Korean J Thorac Cardiovasc Surg       Date:  2011-10-06

2.  Nitric oxide synthetic pathway and cGMP levels are altered in red blood cells from end-stage renal disease patients.

Authors:  Natalia Di Pietro; Annalisa Giardinelli; Vittorio Sirolli; Chiara Riganti; Pamela Di Tomo; Elena Gazzano; Sara Di Silvestre; Christina Panknin; Miriam M Cortese-Krott; Csaba Csonka; Malte Kelm; Péter Ferdinandy; Mario Bonomini; Assunta Pandolfi
Journal:  Mol Cell Biochem       Date:  2016-05-20       Impact factor: 3.396

Review 3.  Inflammation in chronic kidney disease: role in the progression of renal and cardiovascular disease.

Authors:  Douglas M Silverstein
Journal:  Pediatr Nephrol       Date:  2008-12-13       Impact factor: 3.714

4.  Effects of pre- vs. intra-dialysis folic acid on arterial wave reflections and endothelial function in patients with end-stage renal disease.

Authors:  Yuka Tochihara; Malcolm J Whiting; Jeffrey A Barbara; Arduino A Mangoni
Journal:  Br J Clin Pharmacol       Date:  2008-07-11       Impact factor: 4.335

5.  Improving prognosis estimation in patients with heart failure and the cardiorenal syndrome.

Authors:  Husam M Abdel-Qadir; Shaan Chugh; Douglas S Lee
Journal:  Int J Nephrol       Date:  2011-05-18

6.  Aqueous extract of dioscorea opposita thunb. normalizes the hypertension in 2K1C hypertensive rats.

Authors:  Nurmuhammat Amat; Raziya Amat; Sajida Abdureyim; Parida Hoxur; Zulpiya Osman; Dolkun Mamut; Anake Kijjoa
Journal:  BMC Complement Altern Med       Date:  2014-01-21       Impact factor: 3.659

7.  Retrospective single center cohort study: effect of intensive home hemodialysis on right ventricular systolic pressure and clinical outcomes.

Authors:  Michael Girsberger; Christopher T Chan
Journal:  BMC Nephrol       Date:  2020-11-25       Impact factor: 2.388

8.  Association of Pulmonary Hypertension With End-Stage Renal Disease Among the Obese Population.

Authors:  Farah Anum Jameel; Abdul Mannan Junejo; Ayesha Ejaz; Qurat Ul Ain Khan; Kamran Faisal Bhopal; Ahmad Faraz; Syed Hasan Mustafa Rizvi; Fatima Ahmad; Muhammad Tahir
Journal:  Cureus       Date:  2020-08-13

9.  Is There a Correlation between Vitamin C Status and Catecholamines Concentrations in Hemodialysis Patients?

Authors:  Isaline Coquet; Jean-Marc Doise; Jean-Claude Guilland; Catherine Vergely; Christiane Mousson; Luc Rochette
Journal:  Int J Biomed Sci       Date:  2008-06

10.  Effect of Febuxostat on Ambulatory Blood Pressure in Subjects With Hyperuricemia and Hypertension: A Phase 2 Randomized Placebo-Controlled Study.

Authors:  Lhanoo Gunawardhana; Lachy McLean; Henry A Punzi; Barbara Hunt; Robert N Palmer; Andrew Whelton; Daniel I Feig
Journal:  J Am Heart Assoc       Date:  2017-11-04       Impact factor: 5.501

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.